Combination of epigenetic, differentiation and DNA damaging agents induce tumor cell death and stem cell depletion in breast cancer

Gene expression profiles were performed on MDA-MB-231 TNBC cell line treated with entinostast, all-trans retinoic acid (ATRA), and doxorubicin as single, double, and triple combinations using Illumina. Treatment signatures were made from each drug treatment and integrated to find a comprehensive view of changes associated with the epigenetic, differentiation and chemotherapy combination

本研究利用Illumina测序平台（Illumina），对经恩替诺特（entinostast）、全反式维甲酸（all-trans retinoic acid, ATRA）与多柔比星（doxorubicin）单药、双药联合及三药联合处理的MDA-MB-231三阴性乳腺癌（Triple-Negative Breast Cancer, TNBC）细胞系开展基因表达谱（Gene expression profiles）检测。针对每种药物处理分别构建药物处理特征（treatment signatures），并对各特征进行整合分析，以全面揭示与表观遗传调控、细胞分化及化疗联合相关的细胞分子变化。